Background The life time risk of developing heart failure is 20% for Americans over 40 years old. Chronic heart failure (CHF) is becoming a global health problem in the elderly. Previous studies indicate that immune-inflammatory activation plays an important role in the pathogenesis of myocardial fibrosis in CHF. Paeoniflorin (PF) is one of the main effective components of peony, which has been widely used in traditional Chinese medicine for its potent immunomodulatory and anti-inflammatory properties. However, the effects of PF on myocardial fibrosis remain unclear. Objective To exam whether PF protects myocardial fibrosis and improves cardiac function in isoprenaline-induced CHF rats. Methods Age matched male Wistar rats were used in this study. CHF and cardiac remodelling model was established by hypodermic injection of isoprenaline for ten days. After the CHF model establishment, the rats were randomly divided to receive placebo, PF (50 or 100 mg/kg/d, i.g.) or captopril for six weeks. Cardiac remodelling markers including ventricular mass, collagen volume fraction, perivascular collagen area and hydroxyproline concentration were studied. Echocardiography, Masson staining, immunohistochemistry, western blot and real-time PCR were performed. The protein and mRNA expression of PTEN (phosphatase and tensin homolog deleted on chromosome ten) were analysed. Results Compared to the untreated CHF rats, the perivascular collagen area, collagen volume fraction (30.97 ± 4.22% vs 13.75 ± 3.77%), hydroxyproline concentration (4.92 ± 0.78 μg/mg wet weight vs 2.08 ± 0.43 μg/mg wet weight), LVIDd (8.40 ± 0.52 mm vs 6.11 ± 0.58 mm) and LVIDs (6.44 ± 0.93 mm vs 4.49 ± 0.38 mm) were significantly lower in PF-treated (100 mg/kg/d) rats (p < 0.05, n = 8). PF treatment also improved LVEF levels (46.44 ± 3.50% vs 60.89 ± 3.10%). Besides, the expressions of PTEN protein (0.11 ± 0.05 vs 0.63 ± 0.19, p < 0.05) and mRNA (0.22 ± 0.06 vs 0.39 ± 0.02, p < 0.01) were higher in PF-treated rats (n = 3). No damage of renal or liver function was detected in these rats (p > 0.05). Furthermore, we also found that PF can accelerate myocardial fibroblast cell apoptosis and upregulate PTEN signalling in vitro . Conclusions Our findings indicate that PF could alleviate myocardial fibrosis and improve cardiac function in isoprenaline-induced CHF rats by upregulating PTEN signalling pathway. PF may be a potential therapeutic drug for CHF.
Background Nowadays, chronic heart failure (CHF) is a global health problem in the elderly. Over 650 thousand new cases are diagnosed every year in the United States. Previous studies indicate that immune-inflammatory activation plays an important role in the pathogenesis of cardiac remodelling in CHF patients. PG-490, triptolide (TPL), is a diterpene triepoxide with potent immunosuppressive and anti-inflammatory properties and has been used in China for centuries to treat immune-related disorders. However, the effects of TPL on CHF and cardiac remodelling remain unclear. Objective To determine whether TPL can protect myocardial fibrosis and improve cardiac function in isoprenaline-induced CHF rats. Methods Age matched male Wistar rats were used in this study. CHF and cardiac remodelling model was established by hypodermic injection of isoprenaline for ten days. The rats were randomly divided to receive placebo, TPL (20 or 100 μg/kg/d, i.g.) or captopril for six weeks. Cardiac remodelling markers including ventricular mass, collagen volume fraction, perivascular collagen area, collagenI and hydroxyproline concentration were studied. Echocardiography, Masson staining, immunohistochemistry, western blot and real-time PCR were performed. The protein and mRNA expression of PTEN (phosphatase and tensin homolog deleted on chromosome ten) were analysed. Results Compared to the untreated CHF rats, the cardiac remodelling markers, LVEDD (8.40 ± 0.52 mm vs 6.11 ± 0.58 mm) and LVESD (6.44 ± 0.93 mm vs 4.49 ± 0.38 mm) were significantly lower in TPL-treated (100 μg/kg/d) rats (p < 0.05, n = 8). TPL treatment also improved LVEF levels (46.44 ± 3.50% vs 60.89 ± 3.10%, p < 0.05). Besides, the expressions of PTEN protein (0.11 ± 0.05 vs 0.51 ± 0.28, Figure 1) and mRNA (0.22 ± 0.06 vs 0.52 ± 0.01) were higher in TPL-treated rats (p < 0.05, n = 3). No damage of renal or liver function was detected in these rats. Furthermore, we also found that TPL can accelerate myocardial fibroblast cell apoptosis and upregulate PTEN signalling in vitro . Abstract ASSA14-03-43 Figure 1 Effects of TPL on the expression of PTEN protein. TPL = triptolide; PTEN = phosphatase and tensin homolog deleted on chromosome ten; A: normal rats; B: cardiac remodeling rats; C: TPL 20 μg/kg/d; D: TPL 100 μg/kg/d; E: captopril 15 mg/kg/d Conclusions Our findings indicate that TPL could alleviate myocardial remodelling and improve cardiac function in rats by upregulating PTEN signalling pathway. TPL may be a potential therapeutic drug for CHF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.